[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Liquidia Corporation Common Stock (LQDA)

Liquidia Corporation's stock hits a 52-week and all-time high amidst positive trial data and social media buzz, despite ongoing patent litigation concerns.

About Liquidia Corporation Common Stock

Liquidia Corporation is a biopharmaceutical company focused on developing treatments for pulmonary hypertension.
Liquidia Corporation Common Stock uses the ticker $LQDA for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Liquidia Corporation Common Stock (LQDA) social dominance is up XXXXXX% from the previous week.
Liquidia Corporation Common Stock Price hit a 52-Week high of $XXXXX for the hour
Liquidia Corporation Common Stock Price hit an all time of $XXXXX for the hour
Liquidia Corporation Common Stock Galaxy Score™ hit a 52-Week high of XX for the hour
Liquidia Corporation Common Stock Galaxy Score™ hit an all time of XX for the hour
Liquidia Corporation Common Stock entered the top XX AltRank™ for the first time

Price: $XXXXX

Price 24-Hour Time-Series Raw Data
The stock price has reached a 52-week and all-time high of $35.20, driven by positive clinical trial data, strong financial performance, and increasing social media buzz, despite ongoing patent litigation concerns.

24-Hour: -XXXX% 7-Day: -XXXX% 30-Day: XXXXX%

1-Year High: $XX on 2025-12-08
1-Year Low: $XXXXX on 2024-12-19

AltRank: XXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Liquidia Corporation Common Stock (LQDA) is currently AltRank #937 based on combined combined social and market metrics Daily Average: XXX
1-Year High: XXX on 2025-12-11
1-Year Low: XXX on 2025-12-10

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
1-Year High: XX on 2025-12-11
1-Year Low: XX on 2025-12-09

Engagements: XXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XXXX%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXX +231%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-08-08
1-Year Low: XXX on 2025-03-16

Engagements by network (24h): X: XXXXXX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXXXX +68%
X Months: XXXXX +287%
X Year: XXXXX +11%
1-Year High: XXX on 2025-08-03
1-Year Low: XX on 2025-01-27

Mentions by network (24h): X: XXX

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Liquidia Corporation Common Stock (LQDA) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX
X Week: XXX -XX%
X Month: XXX +30%
X Months: XXXXX +286%
X Year: XXXXX +104%
1-Year High: XXX on 2025-06-29
1-Year Low: XX on 2025-01-27

The most influential creators that mention Liquidia Corporation Common Stock in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@pulpmediaoguz	X	XX	X	XXX
@Sulastrisengak	X	XX	X	XXX
@12192Jun	X	XX	X	XXX
@savedo3	X	X	X	XXX
@berkerkcmn	X	XX	X	XXX
@jiquilpan12344	X	XX	X	XXX
@soydasfurkan_	X	XX	X	XXX
@awwww88	X	XX	X	XXX
@Korkmazumut27	X	XX	X	XXX
@An1979Najem100	XX	XX	X	XXX

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -X%
X Month: XX% +1%
X Months: XX% -XX%
X Year: XX% -X%
1-Year High: XXX% on 2025-01-13
1-Year Low: XX% on 2025-03-07

Most Supportive Themes:

Positive Clinical Trial Data and Efficacy: (30%) Posts highlight positive clinical trial data for Yutrepia (treprostinil inhalation powder) and L606, emphasizing superior efficacy and tolerability compared to competitors like United Therapeutics' Tyvaso.
Upcoming Earnings and Financial Performance: (25%) Multiple posts mention upcoming earnings reports for LQDA, indicating anticipation for financial results. Positive financial performance and meeting or exceeding analyst expectations are seen as key drivers for stock price appreciation.
Patent Litigation and Legal Battles: (20%) The ongoing patent disputes between Liquidia (LQDA) and United Therapeutics (UTHR) are a recurring theme. Positive outcomes in these legal battles, such as the denial of preliminary injunctions, are viewed as supportive of LQDA's market entry and growth.

Most Critical Themes:

Legal Overhang and Uncertainty: (40%) Despite positive data, the persistent legal overhang from patent litigation with United Therapeutics (UTHR) creates significant uncertainty. The market's reaction to these legal battles, including potential injunctions, remains a critical factor influencing LQDA's stock price.
Competition and Market Share: (35%) While LQDA's Yutrepia is seen as a superior product, competition from established players like UTHR remains a concern. The ability of LQDA to capture market share and displace competitors is a critical aspect of its long-term success.

Social Dominance: XXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.02%
X Month: XXXXX% +0.0001999999999999988%
X Months: XXXXX% +0.0086%
X Year: XXXXX% +0.0053%
1-Year High: XXXXX% on 2025-08-03
1-Year Low: XXXXXX% on 2025-04-07

Market Dominance: XXXXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-12-08
1-Year Low: XXXXXXX% on 2025-12-11

Market Cap: $XXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
1-Year High: $XXXXXXXXXXXXX on 2025-12-08
1-Year Low: $XXXXXXXXXXXXX on 2025-12-02